XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XRTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.88M
- Forward P/E
- 1.05
- EPS (TTM)
- -$2.09
- Dividend yield
- None
- 52-week range
- 0.81 – 3.60
- Day range
- 0.8101 – 0.878
- Volume / Avg
- 47.88K / 776.48K
- Beta
- —
- Shares outstanding
- 2.25M
52-week range
XRTX stock today
Shares of XORTX Therapeutics (XRTX) finished lower on Nov 20 at $0.839, a drop of 5.73% or $0.051 per share, versus the S&P 500's 3.70% decline. Trading was light, with 47.88K shares changing hands, about 6% of the average daily volume. At this level, XRTX sits near the bottom of its 52-week range of $0.81 to $3.60: 76.7% below the high and 3.6% above the low.
XORTX Therapeutics has posted a net loss over the last twelve months (EPS of -$2.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About XORTX Therapeutics
Company profileXORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Allen Warren Davidoff Ph.D.
- Headquarters
- Calgary, AB
- Website
- xortx.com
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.65 vs —
XRTX news
All XRTX newsXORTX Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs XRTX |
| PPCBPropanc Biopharma Inc. | 1.78 | +3.19% | $1.87M | vs XRTX |
| PPBTPurple Biotech Ltd. ADR | 1.53 | -4.09% | $1.86M | vs XRTX |
| SBFMSunshine Biopharma Inc. | 2.23 | -5.11% | $1.84M | vs XRTX |
| GNPXGenprex Inc. | 1.45 | -13.17% | $1.94M | vs XRTX |
| DCOYDecoy Therapeutics Inc. | 0.8294 | -4.68% | $1.98M | vs XRTX |
| REVBRevelation Biosciences Inc. | 3.50 | -5.15% | $1.99M | vs XRTX |
| ENLVEnlivex Ltd. | 1.05 | -11.76% | $2.01M | vs XRTX |
Indexes, lists and sector
XORTX Therapeutics stock FAQ
What is XORTX Therapeutics's stock price today?
XRTX last traded at $0.839 as of Nov 20, 4:00 PM EST, down 5.73% on the day. Prices are delayed at least 15 minutes.
Who is XORTX Therapeutics's CEO?
Dr. Allen Warren Davidoff Ph.D. is the chief executive officer of XORTX Therapeutics Inc..
What is the XRTX 52-week high?
The 52-week high for XRTX is $3.60 and the 52-week low is $0.81. The stock is currently 76.7% below its high.